Experience with continuous levodopa enteral infusion (Duodopa®)in patients with advanced Parkinson's disease in a secondary level hospital

Article information

Abstract

Introduction

Continuous levodopa delivery by enteral infusion (Duodopa®) is an alternative to deep brain stimulation and subcutaneous apomorphine to control motor fluctuations and dyskinesias in advanced Parkinson's disease (PD). We report our experience with Duodopa® therapy in 11 patients with advanced PD.

Methods

We retrospectively assessed clinical and quality of life changes in all patients with PD with severe motor fluctuations and dyskinesias who started continuous daily levodopa duodenal infusion through percutaneous endoscopic gastrostomy from September 2006 (Duodopa® was approved for advanced PD treatment in Spain at that date) until April 2010 at the A. Marcide Hospital of Spain.

Results

Nine patients received Duodopa® [62.7±10.6 (44–74) years, 63.6% male)]. Pre- Duodopa® clinical characteristics of patients were: disease duration 14.5±8.9 (3–34) years, oral levodopa dose 918.2±277.7 (450–1300) mg/day, and Hoehn and Yahr staging 3.7±0.5 (3–4). Nine patients are still receiving Duodopa®. Patients improved motor fluctuations (72.7% significant improvement), dyskinesia (55.5% significant improvement), daily off-time (90.9%) and daily duration dyskinesia (66.6%) after total infusion time of 170.5 months (3–31). The improvement in Parkinson's Disease Quality of Life Questionnaire-39 (PDQ-39) and Schwab&England Capacity for Daily Living Scale were 38.5±19.8 and 24±12.5 respectively (P<0.05). Equivalent daily dose of levodopa (April 2010) was 1683.4±295.8 (1234–2216) mg/day.

Conclusions

Intraduodenal infusion of levodopa offers an important alternative in treating patients with advanced Parkinson disease

Keywords:

Dyskinesias

Duodopa

Parkinson's disease

Motor fluctuations

Continuous enteral infusion

Levodopa

Resumen

Introducción

La infusión continua de levodopa intraduodenal (Duodopa®) constituye una alternativa a la infusión subcutánea de apomorfina y a la cirugía en pacientes con enfermedad de Parkinson (EP) avanzada. Describimos nuestra experiencia con Duodopa® en pacientes con EP avanzada.

Métodos

Realizamos un estudio epidemiológico, observacional, no intervencionista, poblacional, descriptivo, y retrospectivo, en el que se incluyen todos aquellos pacientes con EP avanzada tratados con Duodopa® por parte de la Sección de Neurología del Hospital A. Marcide de Ferrol hasta abril de 2010.

Resultados

Once de un total de 12 pacientes seleccionados fueron tratados con Duodopa® [63,6% varones; edad media 62,7±10,6 (44–74) años]. En el momento de ser seleccionados para recibir Duodopa® presentaban: tiempo medio de evolución de enfermedad de 14,5±8,9 (3–34) años, dosis media de levodopa oral de 918,2±277,7 (450–1300) mg/ día, y un estadio de Hoehn y Yahr de 3,7±0,5 (3–4). Nueve pacientes mantienen el tratamiento con Duodopa®. Hubo mejoría en las fluctuaciones motoras (72,7% gran mejoría) y discinesias (55,5% gran mejoría) con reducción del tiempo off/día (90,9%) y tiempo con discinesias/día (66,6%) después de un tiempo total de seguimiento con Duodopa® de 170,5 (3–31) meses. La mejoría en las escalas PDQ-39 y Schwab&England fue de 38,5±19,8 y 24±12,5 puntos respectivamente (p<0,05). La dosis media equivalente oral de levodopa (abril 2010) fue de 1683,4±295,8 (1234–2216) mg/día.

Conclusiones

Duodopa® pudiera ser un tratamiento efectivo, seguro, y bien tolerado alternativo a la cirugía y apomorfina subcutánea en pacientes con EP avanzada adecuadamente seleccionados.

Palabras clave:

Discinesias

Duodopa

Enfermedad de Parkinson

Fluctuaciones motoras

Infusión continua enteral

Levodopa

Full text is only aviable in PDF

References

[1.]

U.K. Rinne.

Problems associated with long-term levodopa treatment of Parkinson's disease.

Acta Neurol Scand, 95 (1983), pp. 19-26

Medline

[2.]

S. Fahn.

How do you treat motor complications in Parkinson's disease: Medicine, surgery, or both?.

Ann Neurol, 64 (2008), pp. S56-S64

http://dx.doi.org/10.1002/ana.21453 | Medline

[3.]

W. Poewe, G.K. Wenning, Apomorphine:.

an underutilized therapy for Parkinson's disease.

Mov Disord, 5 (2000), pp. 789-794

[4.]

P. Krack, A. Batir, N. van Blercom, S. Chabardes, V. Fraix, C. Ardouin, et al.

Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease.

N Engl J Med, 349 (2003), pp. 1925-1934

http://dx.doi.org/10.1056/NEJMoa035275 | Medline

[5.]

E. Bredberg, D. Nilsson, K. Johansson, S.M. Aquilonius, B. Johnels, C. Nyström, et al.

Intraduodenal infusion of a waterbased levodopa dispersion for optimisation of the therapeutic effect in severe Parkinson's disease.

Eur J Clin Pharmacol, 45 (1993), pp. 117-122

Medline

[6.]

D. Nyholm, T. Lewander, A. Johansson, P.A. Lewitt, C. Lundqvist, S.M. Aquilonius.

Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure.

Clin Neuropharmacol, 31 (2008), pp. 63-73

http://dx.doi.org/10.1097/WNF.0b013e3180ed449f | Medline

[7.]

R.M. Yañez-Baña.

Infusión de Duodopa® en la enfermedad de Parkinson.

Revista Española de Trastornos del Movimiento, 7 (2007), pp. 21-25

[8.]

M.M. Hoenh, M.D. Yahr, Parkinsonism:.

onset, progression and mortality.

Neurology, 17 (1967), pp. 427-442

Medline

[9.]

R.S. Schwab, A.C. England.

Projection technique for evaluating surgery in Parkinson's disease.

Third Symposium on Parkinson's disease, pp. 152-157

[10.]

V. Peto, C. Jenkinson, R. Fitzpatrick, R. Greenhall.

The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease.

Qual Life Res, 4 (1995), pp. 241-248

Medline

[11.]

ECDEU assessment manual for psychopharmacology, pp. p.217-p.222

[12.]

M.L. Welter, J.L. Houeto, L. Tezenas du Montcel, M.L. Welter, J.L. Houeto, S. Tezenas du Montcel, et al.

Clinical predictive factors of subthalamic stimulation in Parkinson's disease.

Brain, 125 (2002), pp. 575-583

Medline

[13.]

D. Nilsson, D. Nyholm, S.M. Aquilonius.

Duodenal levodopa infusion in Parkinson's disease–long-term experience.

Acta Neurol Scand, 104 (2001), pp. 343-348

Medline

[14.]

A. Antonini, I.U. Isaias, M. Canesi, M. Zibetti, F. Mancini, L. Manfredi, et al.

Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome.

Mov Disord, 22 (2007), pp. 1145-1149

http://dx.doi.org/10.1002/mds.21500 | Medline

[15.]

F. Valldeoriola.

Continuous duodenal levodopa infusion - The Barcelona Experience.

European Neurological Review Suppl.III International Forum on Advanced Parkinson's Disease, 3 (2008), pp. 25-28

[16.]

D. Devos, for the French DUODOPA Study Group.

Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease.

Mov Disord, 24 (2009), pp. 993-1000

http://dx.doi.org/10.1002/mds.22450 | Medline

[17.]

V. Puente, O. de Fabregues, C. Oliveras, G. Ribera, C. Pont-Sunyer, R. Vivanco, et al.

Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson's disease: Impact on control of fluctuations and quality of life.

Parkinsonism Relat Disord, 16 (2010), pp. 218-221

http://dx.doi.org/10.1016/j.parkreldis.2009.07.015 | Medline

[18.]

J.S. Reijnders, U. Ehrt, W.E. Weber, D. Aarsland, A.F. Leentjens.

A systematic review of prevalence studies of depression in Parkinson's disease.

Mov Disord, 23 (2008), pp. 183-189

http://dx.doi.org/10.1002/mds.21803 | Medline

[19.]

D. Nyholm, A.I. Nilsson Remahl, N. Dizdar, R. Constantinescu, B. Holmberg, R. Jansson, et al.

Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.

Neurology, 64 (2005), pp. 216-223

http://dx.doi.org/10.1212/01.WNL.0000149637.70961.4C | Medline

[20.]

N. Syed, J. Murphy, T. Zimmerman Jr., M.H. Mark, J.I. Sage.

Ten years’ experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease.

Mov Disord, 13 (1998), pp. 336-338

http://dx.doi.org/10.1002/mds.870130222 | Medline

[21.]

D. Nyholm, H. Askmark, C. Gomes-Trolin, T. Knutson, H. Lennernäs, C. Nyström, et al.

Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets.

Clin Neuropharmacol, 26 (2003), pp. 156-163

Medline

[22.]

A. Antonini, F. Mancini, M. Canesi, R. Zangaglia, I.U. Isaias, L. Manfredi, et al.

Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease.

Neurodegener Dis, 5 (2008), pp. 244-246

http://dx.doi.org/10.1159/000113714 | Medline

[23.]

H. Honig, A. Antonini, P. Martinez-Martin, I. Forgacs, G.C. Faye, T. Fox, et al.

Intrajejunal levodopa infusion in Parkinson's disease: A pilot multicenter study of effects on nonmotor symptoms and quality of life.

Mov disord, 24 (2009), pp. 1468-1474

http://dx.doi.org/10.1002/mds.22596 | Medline

[24.]

M.M. Mouradian, I.J. Heuser, F. Baronti, T.N. Chase.

Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease.

Ann Neurol, 27 (1990), pp. 18-23

http://dx.doi.org/10.1002/ana.410270105 | Medline

[25.]

A. Antonini.

Continuous dopaminergic stimulation–from theory to clinical practice.

Parkinsonism Relat Disord, 13 Suppl (2007), pp. S24-S28

http://dx.doi.org/10.1016/j.parkreldis.2007.06.002 | Medline

[26.]

D. Nyholm, R. Jansson, T. Willows, I.N. Remahl.

Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements.

Neurology, 65 (2005), pp. 1506-1507

http://dx.doi.org/10.1212/01.wnl.0000183146.78892.3f | Medline

[27.]

D. Santos-García, M. Macias, M. Llaneza, A. Aneiros.

Suicide following duodenal levodopa infusion for Parkinson's disease.

Mov Disord, 24 (2009), pp. 2029-2030

http://dx.doi.org/10.1002/mds.22708 | Medline

[28.]

A. Antonini, E. Tolosa.

Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: selection criteria and patient management.

Expert Rev Neurother, 9 (2009), pp. 859-867

http://dx.doi.org/10.1586/ern.09.48 | Medline

[29.]

C. Sánchez-Castañeda, J. Campdelacreu, J. Miró, M. Juncadella, S. Jaumà, M. Calopa.

Cognitive improvement after duodenal levodopa infusion in cognitively impaired Parkinson's disease patients.

Prog Neuropsychopharmacol Biol Psychiatry, 34 (2010), pp. 250-251

http://dx.doi.org/10.1016/j.pnpbp.2009.10.021 | Medline

☆

This work has been (partially) presented as an oral communication at the last meeting of the Spanish Neurology Society, which took place in Barcelona on November 17–21, 2009.

Indexed in:

Follow us:

Indexed in:

Follow us:

Subscribe to our newsletter